BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.130
-0.010 (-0.88%)
May 22, 2026, 4:00 PM EDT - Market closed

BioXcel Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
-0.642.271.380.38-
Revenue Growth (YoY)
--71.67%64.20%268.00%--
Cost of Revenue
0.430.162.141.260.02-
Gross Profit
-0.010.480.120.120.36-
Selling, General & Admin
21.9920.4934.4983.4168.7654.23
Research & Development
28.6530.2530.4484.3391.2452.71
Other Operating Expenses
0.190.192.444.16--
Total Operating Expenses
50.8350.9467.37171.9160106.94
Operating Income
-50.59-50.46-67.25-171.78-159.65-106.94
Interest Income
11.072.65.652.530.04
Interest Expense
-17.19-16.98-15.13-13.31-8.21-0.04
Other Non-Operating Income (Expense)
-8.56-3.5220.170.39-0.43-
Total Non-Operating Income (Expense)
-24.75-19.447.65-7.27-6.110
Pretax Income
-75.33-69.9-59.6-179.05-165.76-106.93
Net Income
-75.33-69.9-59.6-179.05-165.76-106.93
Net Income to Common
-75.33-69.9-59.6-179.05-165.76-106.93
Shares Outstanding (Basic)
17123222
Shares Outstanding (Diluted)
17123222
Shares Change (YoY)
417.46%381.58%39.21%4.00%6.23%21.63%
EPS (Basic)
-4.52-5.73-23.51-98.33-94.72-64.80
EPS (Diluted)
-4.52-5.73-23.51-98.33-94.72-64.80
Shares Outstanding
27.0822.333.11.871.761.75
Free Cash Flow
-57.38-57.62-72.03-155.03-135.48-82.6
Free Cash Flow Per Share
-3.40-4.72-28.41-85.13-77.38-50.11
Gross Margin
-74.45%5.43%8.70%94.67%-
Operating Margin
--7859.97%-2967.56%-12448.00%-42572.00%-
Profit Margin
--10887.40%-2630.14%-12974.90%-44201.90%-
FCF Margin
--8974.30%-3178.60%-11233.80%-36128.00%-
EBITDA
-50.3-50.16-66.94-171.46-159.32-106.64
EBITDA Margin
--7813.24%-2953.93%-12424.90%-42484.80%-
EBIT
-50.59-50.46-67.25-171.78-159.65-106.94
EBIT Margin
--7859.97%-2967.56%-12448.00%-42572.00%-
Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q